Nourishing Our Roots: A Juneteenth Celebration of Heritage and Wellness
Chicago, IL, May 29, 2025 (GLOBE NEWSWIRE) --
Black Girl Vitamins (BGV), a brand committed to empowering the Black community, today announced its comprehensive "Nourishing Our Roots" campaign in honor of Juneteenth. The theme encourages Black women to reflect on the deep historical roots of their heritage, which face ongoing risks of erasure, and to prioritize the roots of their wellness, essential for maintaining health in a world that often fails to prioritize their needs.Black Girl Vitamins believes that Juneteenth, celebrating the end of slavery in the United States, has evolved beyond a mere holiday; it represents a crucial act of cultural preservation. The campaign underscores BGV's unwavering commitment to reminding its audience of the power, heritage, and well-being found inherently within the Black community. The brand will honor the holiday with a special sale, exclusive bonus gifts, a commemorative brand photoshoot, and a nationwide Juneteenth event tour. A portion of all proceeds will directly support BGV's ongoing commitment to empowering aspiring medical students.
Juneteenth Sale and Limited-Edition Gifts
To kick off the celebration, Black Girl Vitamins will host a special Juneteenth sale from June 16 to June 20. The sale will include their famous BGV's Collagen Powder, a kitchen essential, extremely versatile and easy to use. This collagen powder dissolves within seconds and blends seamlessly with any meal, making it an effortless addition to daily nutrition by seamlessly incorporating this collagen into cultural foods, simultaneously enriching the body with added protein.
This supplement is designed to promote joint health, enhance bone strength, improve skin elasticity, and offer numerous other benefits, aligning with the campaign's focus on holistic wellness. As an additional token of appreciation and celebration, BGV will include limited-edition gifts such as commemorative BGV pins, satin bonnets, convenient pill cases, and exclusive Juneteenth postcards in the first 2,000 orders placed during the sale! Customers can apply the discount code NOURISH19 for orders totaling $60 and over.
Commemorative Photoshoot Captures Black Joy
Reinforcing the "Nourishing Our Roots" theme, Black Girl Vitamins will unveil a specially curated 90s cookout-themed brand photoshoot. This visual campaign is designed to be a vibrant representation of Black culture, joy, and community in its rawest and most authentic form. The imagery aims to evoke feelings of nostalgia, warmth, and collective celebration, showcasing the beauty and resilience inherent in Black heritage.
The photoshoot will serve as a powerful visual anchor for the campaign, emphasizing the importance of cultural preservation through shared experiences and unadulterated joy. It will be disseminated across BGV's digital platforms, inspiring and connecting with audiences nationwide.BGV Juneteenth Event Tour Connects Communities
To engage directly with and uplift local communities across the country, Black Girl Vitamins will embark on a multi-city Juneteenth event tour, sponsoring and/or having a significant presence at various celebrations. This tour underscores BGV's dedication to fostering community connections and extending its message beyond e-commerce.
A major highlight of the tour includes Black Girl Vitamins' sponsorship of Refine Collective's 5th Annual Juneteenth Freedom Market in Chicago. This prominent event is expected to draw over 3,000 attendees, offering a vibrant atmosphere with more than 70 vendors, diverse food options, lively music, and positive vibes, all converging to nourish culture in BGV's home base.
Engaging Audiences at Key Locations
The tour continues with a significant presence at Amazon HQ2's Juneteenth Event on June 19, 2025, in Arlington, Virginia (1400 South Eads Street, 501 15th St.). Black Girl Vitamins willbe one of only a few select brands featured at this large-scale corporate celebration, which anticipates over 3,000 attendees. This engagement provides a unique opportunity for BGV to connect with a diverse professional audience and further its mission of wellness and empowerment.
Beyond these major events, the BGV team plans to make additional stops across the country. These engagements are designed to allow the brand to connect personally with customers, further foster community, and share product samples in some cities. Planned stops include Atlanta, Georgia; Detroit, Michigan; Grand Rapids, Michigan; New Orleans, Louisiana; and Columbus, Ohio, ensuring a wide national reach for their Juneteenth celebration.
Through these multifaceted initiatives – from a special sale focused on nutritional essentials and exclusive gifts to a commemorative photoshoot and a broad national event tour – Black Girl Vitamins is not just honoring Juneteenth. It is actively engaging in cultural preservation and promoting holistic wellness within the Black community, reinforcing its commitment to empowerment and supporting the next generation of medical professionals.
For more details and updates, visit blackgirlvitamins.co or follow them on Instagram. About Black Girl Vitamins
Black Girl Vitamins (BGV) is a Black-owned health and wellness brand dedicated to addressing the unique nutritional needs of Black women. Founded with expert guidance from Dr. Standifer-Barrett, Dr. C Nicole Swiner, and Dr. Chinyere Okpaleke, BGV offers science-backed, high-quality supplements formulated to combat health disparities such as Vitamin D deficiency, anemia, and Polycystic Ovarian Syndrome (PCOS). Currently available at Amazon.com and online through their website, BGV empowers Black women to thrive in their wellness journeys. With a commitment to representation and community, BGV partners with Black medical professionals, sponsors initiatives like the $100,000 scholarship fund for Black women pursuing healthcare-related degrees, and collaborates with organizations such as Howard Women's Basketball. Since its founding, BGV has reached over 200,000 women, building a community driven by health, empowerment, and inclusivity. Learn more at www.blackgirlvitamins.com.
CONTACT: Heather Holmes heather@publicityforgood.com 1+(828)332-5307 publicityforgood.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Insider
an hour ago
- Business Insider
Novartis announces data from new subgroup analysis of Phase III NATALEE trial
Novartis (NVS) is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali plus endocrine therapy in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, EBC, at high risk of recurrence across age and menopausal status. The data will be presented at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Results at median follow-up of 44.2 months show that patients receiving Kisqali continued to see consistent reductions in risk of recurrence across all efficacy measures, regardless of age and menopausal status. In this one-year post-treatment analysis, pre-menopausal and younger patients, who often present with more aggressive disease characteristics, experienced greater reductions in risk of recurrence and fewer treatment discontinuations due to adverse events than post-menopausal patients. Results include: 33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer patients receiving Kisqali in 1-year post-treatment analysis; Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients; Separate real-world analysis presented at ASCO demonstrates differences in treatment outcomes that underscore critical need to improve care for Black patients with EBC. Confident Investing Starts Here:
Black America Web
2 hours ago
- Black America Web
Redistricting: Majority Black Voting Maps Rejected In Louisiana
Source: Mario Tama / Getty One of the most innocuous yet insidious ways voter suppression rears its head is through redistricting, a process by which a state legislature draws up voting maps along political lines. Despite a federal judge finding that their current legislative map violates the Voting Rights Act, Louisiana lawmakers have rejected a new map that would've included eight new, majority Black districts. The Louisiana Illuminator reports that Bill 487 and Bill 488, which would've redrawn the legislative maps for the Senate and House of Representatives, respectively, were struck down in a 9-6 and 9-5 vote that fell along party lines. The current maps were drawn in 2022 and utilized census data from 2010, despite the fact that the state's Black population has only increased over the last decade. Black voters make up a third of Louisiana's population, but the current voting maps only have one majority Black district. Rep. Edmond Jordan (D-Baton Rouge), ithe chairman of the Louisiana Legislative Black Caucus, authored both bills. He explained the changes were necessary to address a ruling by a federal judge last year that found the current map disenfranchised Black voters. 'By us not upholding our obligation and redrawing these maps … I think it sends a signal that we are unwilling to do so,' Jordan told his fellow legislators. 'Rather than wait on the court to come up with a decision, I think it's incumbent upon us to get ahead of that and maybe draw these maps and show the court that we're willing to comply with Section 2' of the Voting Rights Act. The Republican opposition explained that they didn't feel the need to update the maps as the ruling is currently under appeal, and they believe that the courts will rule in their favor. They also brought up concerns that the new district lines would require current elected officials to move in order to still represent their district or possibly have to run against another incumbent to maintain their seat in the legislature. Jordan understood those concerns but stated his priority was giving Black voters an equal voice in determining who represents them. 'What we're trying to do is attempt to unpack and uncrack these districts so that they would comply with Section 2,' Jordan said. Source: Juan Silva / Getty From the Louisiana Illuminator: Packing is a type of gerrymandering that forces a large number of voters from one group into a single or small number of districts to weaken their power in other districts. Cracking dilutes the power of those voters into many districts. Jordan's plan would have added new majority Black House districts in Natchitoches, Lake Charles, Shreveport and Baton Rouge, and Black Senate districts in Baton Rouge, Shreveport and Jefferson Parish. In what can only be described as saying the quiet part out loud, state Republicans added that they found Section 2 of the Voting Rights Act to be outdated. For clarity, Section 2 of the Voting Rights Act prevents any voting law or measure 'which results in a denial or abridgement of the right of any citizen of the United States to vote on account of race or color.' Considering that they're actively using legislative districts to curb the power of Black votes, it's clear Section 2 is still a necessity to maintain voting rights within majority Black communities. Redistricting is always a partisan affair, with the legislative map being drawn by whatever party has power. Far too often, though, the redistricting efforts by state Republicans are largely built around minimizing Black voting power to keep Republicans in office. This isn't only an issue in Louisiana, as several states have drawn legislative maps that explicitly undermine Black votes. Redistricting plans in the state of Texas are also facing legal challenges due to allegations of racism. There's an ongoing fight in Texas's Tarrant County over redistricting plans that several state legislators believe violate the Voting Rights Act, and there's currently a federal case underway against the Texas state government over its 2021 voting map that was believed to have 'diluted the power of minority voters.' One of the worst offenders is Alabama, whose redistricting efforts have been deemed racist by federal judges several times. State Republicans have said that if they don't receive a favorable ruling in their appeal on the decision, they won't update the voting map until 2030 to avoid federal oversight. There is nothing more on brand for the modern GOP than having a temper tantrum when being told to be less racist. If anything, this is a reminder that in America, the boring, procedural racism is often the worst kind. SEE ALSO: Poll Shows Companies Maintaing DEI Intiatives Have Better Reputations MIT Becomes Latest University To Back Away From DEI Initiatives SEE ALSO Redistricting: Majority Black Voting Maps Rejected In Louisiana was originally published on Black America Web Featured Video CLOSE
